Sunpointe LLC Acquires 636 Shares of Sanofi (NASDAQ:SNY)

Sunpointe LLC grew its stake in shares of Sanofi (NASDAQ:SNY) by 13.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,374 shares of the company’s stock after buying an additional 636 shares during the quarter. Sunpointe LLC’s holdings in Sanofi were worth $298,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Cardinal Capital Management boosted its position in Sanofi by 0.3% during the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock valued at $3,827,000 after buying an additional 199 shares during the period. Gradient Investments LLC raised its stake in shares of Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock valued at $542,000 after acquiring an additional 200 shares during the last quarter. Perigon Wealth Management LLC raised its stake in shares of Sanofi by 3.1% during the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock valued at $367,000 after acquiring an additional 201 shares during the last quarter. Beacon Financial Group boosted its holdings in shares of Sanofi by 1.6% during the first quarter. Beacon Financial Group now owns 14,398 shares of the company’s stock worth $799,000 after purchasing an additional 222 shares during the period. Finally, AdvisorNet Financial Inc grew its stake in shares of Sanofi by 16.4% in the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock worth $89,000 after purchasing an additional 227 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Trading Up 0.5%

NASDAQ SNY opened at $50.37 on Monday. The firm has a market capitalization of $123.53 billion, a PE ratio of 17.99, a P/E/G ratio of 1.15 and a beta of 0.48. The stock’s 50 day moving average is $49.54 and its 200 day moving average is $52.15. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the firm posted $1.78 earnings per share. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. Research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price for the company. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research report on Monday, June 2nd. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.